Movement Disorders

Alberto J. Espay, Thomas Maloney, Jennifer Vannest, Matthew M. Norris, James C. Eliassen, Erin Neefus, Jane B. Allendorfer, Robert Chen, Jerzy P. Szaflarski November 11, 2017

ABSTRACT

Objective

We sought to determine whether abnormalities in emotion processing underlie functional (psychogenic) dystonia, one of the most common functional movement disorders.

Methods

Motor and emotion circuits were examined in 12 participants with functional dystonia, 12 with primary organic dystonia, and 25 healthy controls using functional magnetic resonance imaging at 4T and a finger-tapping task (motor task), a basic emotion-recognition task (emotional faces task), and an intense-emotion stimuli task.

Read More...
Stefanie Lerche, Claudia Schulte, Karin Srulijes, Andrea Pilotto, Tim W. Rattay, Ann-Kathrin Hauser, Elke Stransky, Christian Deuschle, Ilona Csoti, Ingolf Lachmann, Henrik Zetterberg, Inga Liepelt-Scarfone, Thomas Gasser, Walter Maetzler, Daniela Berg, Kathrin Brockmann November 2, 2017

ABSTRACT

Background

A proportion of idiopathic Parkinson’s disease patients (PDidiopathic) with dementia show altered CSF profiles of amyloid β (Aβ) and Tau. PD patients with Glucocerebrosidase (GBA) mutations (PDGBA) present with even more cognitive decline than seen in PDidiopathic.

Read More...
Weihua Li, Nick P. Lao-Kaim, Andreas A. Roussakis, Antonio Martín-Bastida, Natalie Valle-Guzman, Gesine Paul, Clare Loane, Håkan Widner, Marios Politis, Tom Foltynie, Roger A. Barker, Paola Piccini October 30, 2017

Abstract

Background

18F-dopa PET measuring aromatic l-amino acid decarboxylase activity is regarded as the gold standard for evaluating dopaminergic function in Parkinson’s disease. Radioligands for dopamine transporters are also used in clinical trials and for confirming PD diagnosis. Currently, it is not clear which imaging marker is more reliable for assessing clinical severity and rate of progression.

Read More...
Shahmir Sohail, Lei Yu, Julie A. Schneider, David A. Bennett, Aron S. Buchman, Andrew S. P. Lim October 30, 2017

ABSTRACT

Introduction

Patients with Parkinson’s disease (PD) frequently experience disrupted sleep, and several sleep abnormalities are associated with an increased risk of incident PD. However, there are few data concerning the relationship between objectively quantified sleep disruption and the cardinal histopathological features of PD, especially in individuals without clinical PD.

Read More...
Shunsuke Koga, Adam Parks, Koji Kasanuki, Monica Sanchez-Contreras, Matthew C. Baker, Keith A. Josephs, J. Eric Ahlskog, Ryan J. Uitti, Neill Graff-Radford, Jay A. van Gerpen, Zbigniew K. Wszolek, Rosa Rademakers, Dennis W. Dickson October 30, 2017

Abstract

Background

Cognitive impairment is one of the core features of progressive supranuclear palsy. This study aimed to clarify the profile of cognitive impairment and its underlying pathology in progressive supranuclear palsy.

Methods

We retrospectively reviewed medical records to evaluate the pattern and severity of cognitive impairment in 121 autopsy-confirmed progressive supranuclear palsy patients.

Read More...
Jost-Julian Rumpf, Jana Albers, Christopher Fricke, Wolf Mueller, Joseph Classen October 30, 2017

ABSTRACT

Background: Methamphetamine abuse has been linked to an increased risk of Parkinson’s disease.

Objective: The objective of this study was to investigate structural abnormality of the substantia nigra in past methamphetamine users using transcranial sonography.

Methods: In a cross-sectional, observational study, echogenicity of the substantia nigra was assessed in 59 past methamphetamine users and 59 matched controls.

Read More...

Andoird App
Loading...